Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

3 weeks ago

HAMPTON, N.J., Oct. 26, 2024 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria ( CIndU ) -cold urticaria ( ColdU ) and ...

Ticker	Sentiment	Impact
CLDX	Neutral	5 %